Dipartimento di Chimica e Tecnologie Farmaceutiche, Università degli Studi di Palermo, Via Archirafi 32, 90123 Palermo, Italy.
Curr Top Med Chem. 2011;11(18):2382-9. doi: 10.2174/156802611797183276.
In the last twenty years a depth study on potential pharmaceutical applications of synthetic polymers at proteinlike structure as carrier for macromolecular prodrug production has been performed in academia and in industry. In particular α,β-poly(N-2-hydroxyethyl)-DL-aspartamide (PHEA), α,β-polyaspartylhydrazide (PAHy), poly(glutamic acid) (PGA), poly(aspartic acid) (PAA) and polylysine (PLL) have been extensively studied in this field. In the present review, the use of PHEA, PAHy, PGA as starting materials to prepare macromolecular prodrugs is reported and drug delivery and targeting aspects have been considered.
在过去的二十年中,学术界和工业界对合成聚合物在蛋白质样结构中的潜在药物应用进行了深入研究,将其作为生产大分子前药的载体。特别是α,β-聚(N-2-羟乙基)-DL-天冬酰胺(PHEA),α,β-聚天冬酰肼(PAHy),聚谷氨酸(PGA),聚天冬氨酸(PAA)和聚赖氨酸(PLL)在该领域得到了广泛研究。在本综述中,报告了使用 PHEA、PAHy、PGA 作为起始材料来制备大分子前药,并考虑了药物传递和靶向方面。